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Drug dependency in adult and paediatric patients with inflammatory bowel disease (IBD) is
described and the significance of this response pattern in clinical practice discussed in this review.
Dependent patients maintain remission while on the treatment, but they relapse shortly after drug
cessation or dose decrease. However, a quick restoration of remission and sustained response is
achieved when the therapy is re-introduced or dose increased.
Population-based studies have demonstrated that 22–36% of adults and 14–50% of children become
corticosteroid dependent. Approximately 1/4–1/3 of treated patients undergo surgery ≤1 year after
treatment start, although newer paediatric studies reported lower risk of surgery (5–11%), including
dependent patients. The frequent use of immunosuppressants (68–80% of children) might explain this
favourable outcome and thus reduce importance of the term corticosteroid dependency.
Infliximab dependency was described in 42–66% of children and 29% of adults with Crohn's
disease. The risk of surgery 50 and 40 months after treatment start was 10% and 23% in infliximab
dependent children and adults, respectively. Maintenance of infliximab in dependent patients
was suggested to postpone if not avoid the need of surgery.
Lastly, mesalazine dependency was identified in 23% of adults with Crohn's disease. These patients
were characterized by mild disease course and lower surgical risk compared to non-responders to
mesalazine (32 vs. 61%).
Identification of drug dependency is useful for prediction of a certain disease course and surgery.
An adjustment of medical therapy may alter the prognosis and disease course.
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Inflammatory bowel disease (IBD) is a chronic disorder of
unknown aetiology and various manifestations regarding
disease localization, occurrence of complications and frequen-
cy of relapses.1 According to this, different behaviour patterns
and disease courses have been identified classifying patients
into several subtypes.2–4 Patients, however, differ also in
response patterns – response/no response – a phenotype
“drug dependency” has been described in children and adults
with IBD.5–7 The dependent patients represent a specific
population of individuals who maintain remission while on the
treatment, but relapse promptly after drug cessation or dose
decrease.However, a quick restoration of remission, repeating
the way of former response, is achieved and sustained when
the therapy is re-introduced or dose increased.
Drug dependency was first described in corticosteroid
therapy,5 later in infliximab treatment 7–9 and most recently
in the use of mesalazine preparations.10
The aim of this review is to describe drug dependencies in
paediatric and adult patients with IBD and to elucidate the
significance of this response pattern in clinical practice.2. Corticosteroid dependency
2.1. The development of the term corticosteroid
dependency
Corticosteroid dependency was first introduced in an
inception cohort of adult Crohn's disease (CD) patients fromCopenhagen County in 1994.5 In this study, the first steroid
treatment course was evaluated in 109/196 CD patients
diagnosed between 1979 and 1987. Later, Faubion et al. 11
published a population-based study assessing the course of
the initial corticosteroid treatment in 74/173 CD patients
and 63/185 patients with ulcerative colitis (UC) diagnosed in
Olmsted county from 1970 to 1993. Furthermore, the
outcome of corticosteroid treatment has been studied in
several non-population based cohorts.12–16
Four paediatric studies of unselected cohorts have also
addressed the term corticosteroid dependency.6,17-19 In
addition, two paediatric studies based on prospective
multicentre database from US and Canada 20,21 assessed
the outcome of the first steroid course in newly diagnosed
children with IBD.
The term corticosteroid dependency was recognized as an
important clinical response pattern and the definition has
been implemented to the European Crohn's and Colitis
Organization (ECCO) guidelines for CD and UC in 2006 and
2008 and has also been accepted by the Food and Drug
Administration (FDA) agency as one of the end points for
randomized controlled trials. 22,23
The different definitions of corticosteroid dependency
are summarized in Table 1.2.2. How many become corticosteroid dependent?
From the population-based studies it is known that 28–36% of
CD adult patients and 22% of UC patients became cortico-
steroid dependent.5,11 Among paediatric patients, 24–39% of
children with CD and 14–50% of those with UC developed
Table 1 Definitions of corticosteroid dependency.
Author Definition
Munkholm et al. 5 (1994) Relapse within 30 days after treatment had finished or relapse at dose reduction
impeding discontinuation of prednisolone treatment for more than one year.
Faubion et al. 11 (2001) Continued corticosteroid (CS) therapy at year-end caused by relapse after CSs
were discontinued or caused by relapse at dose reduction impeding
discontinuation of CS therapy.
Tung et al. 6 (2006) Relapse within 30 days of treatment cessation or relapse when dose reduction
was attempted.
ECCO guidelines on Crohn's disease 22 (2006) Relapse when the steroid dose is reduced below 20 mg/day, or within 6 weeks of
stopping steroids.
ECCO guidelines on ulcerative colitis 23 (2008) Inability to reduce steroid below the equivalent of prednisolone
10 mg/day within 3 months of starting steroids, without recurrent active disease
or relapse within 3 months of stopping steroids.
Jakobsen et al. 17 (2010) Relapse within 30 days after steroid was stopped or the need for azathioprine or
6-mercaptopurine, methotrexate or anti-TNF to end steroid treatment due to
relapse during tapering of steroids.
83Drug dependency in inflammatory bowel diseasecorticosteroid dependency 6,17-19 (Table 2). Similar results
were observed in two multicentre studies with 31% of CD and
43% of UC children becoming steroid dependent.20,21
The frequency of steroid dependency in adult studies of
selected cohorts ranges from 7.5 to 58% of patients with CD
and from 17 to 47% of those with UC.12–162.3. What does corticosteroid dependency imply in
terms of surgery?
In the study by Munkholm et al. 5 one month after cessation of
corticosteroid therapy, 59% of non-responders and 26% of
corticosteroid dependent patients, respectively, underwent
surgical intervention. None of those with prolonged response
had surgery within this time period. However, no significant
difference in surgery rate among the response groups has been
observed during the following two years.
Faubion et al. 11 described that cumulative probability of
surgery 12 months after the start of corticosteroid treatment
was 38% in CD and 29% in UC patients. No specification







Munkholm et al. 5 109 48 (44) 39 (
Faubion et al. 11 74 24 (32) 21 (
Paediatric study
Tung et al. 6 26 11 (42) 8 (
Vernier-Massouille et al. 18 343 243 (71) 83 (
Gower-Rousseau et al. 19 – – –
Jakobsen et al. 17 82 50 (61) 32 (
n = number of patients treated with corticosteroids.The risk of resection one year after the initial course of
corticosteroids was 27% in CD and 29% in UC children as
reported by Tung et al. 6, again without specification as to
corticosteroid outcome.
Finally, in the most recent paediatric study17 the
cumulative probability of surgery one year after start of
corticosteroid treatment was 11.5% and 7.8% for CD and UC.
Interestingly, when stratifying for outcome 30 days after
stopping corticosteroids, the risk of surgery was equal for
steroid dependent patients and patients with prolonged
response in both CD and UC. Similar low risk of surgery was
observed in two multicentre studies 20,21 where 8% and 5% of
children with CD and UC respectively underwent surgery for
IBD within one year after start of corticosteroids.
2.4. Are there any predictors for corticosteroid
dependency?
No predictor of treatment response has been identified in
any of the studies of unselected cohorts assessing adult
patient populations,5,11 whereas the paper by Jakobsen








36) – – –
28) 63 31 (49) 14 (22)
31) 14 8 (57) 2 (14)
24) – – –
77 47 (61) 20 (26)
39) 77 38 (50) 38 (50)
84 D. Duricova et al.involving terminal ileum at diagnosis were at increased risk
of steroid dependency.173. Infliximab dependency
3.1. The development of the term infliximab
dependency
Dependent response pattern was recognized in infliximab
treatment first in 2006.7 Some patients maintained the
remission after induction therapy alone or induction and one
year maintenance therapy, while others relapsed and
required further infusions to sustain the initial response.24,25
This phenotype model was first developed and evaluated in a
cohort of 24 children with CD treated in Denmark from 1999
to 2003.7 Infliximab dependency was assessed 90 days after
the intended treatment cessation and patients relapsing
within this time period but regaining the initial response
after re-introduction of infliximab were considered as
infliximab dependent.
The model was later adjusted (Fig. 1) and used in a
subsequent study of 82 paediatric CD patients treated with
infliximab.9 The study was an extension of the previous one 7
and included patients from Denmark and the Czech Republic,
treated with infliximab from 2000 to 2006.
Furthermore, a national cohort of CD children from the
Netherlands has been assessed for infliximab dependency.8
Sixty-six children, treated from 2002 to 2007, were included
and considered as infliximab dependent in case of relapse of
symptoms requiring repeated infusions to regain good
clinical response.
Lastly, infliximab dependency has been studied in a
cohort of adult CD patients.26 In 132 patients from Denmark
and 115 patients from the Czech Republic, treated 1999–
2006, infliximab outcome was evaluated according to aFigure 1 The phenotype model of infliximab (IFX) dependency.
methotrexate, other biologicals. ⁎⁎intestinal (resection, strictureplasty
and advancement flap).phenotype model developed and used in a previous paedi-
atric study.9
3.2. How many patients developed infliximab
dependency?
In paediatric studies 42–66% of children became infliximab
dependent, whereas 15–29% maintained initial response as
prolonged responders.7–9 In contrast, a study of adult
patients found that 49% of the patients were prolonged
responders and only 29% became infliximab dependent.26
The results are summarized in Table 3.
3.3. What does infliximab dependency imply in term
of surgery?
Three articles reported risk of surgery.8,9,26 In the Danish-
Czech study,9 the cumulative probability of surgery 50
months after the start of infliximab was 10% in infliximab
dependent children, 30% in prolonged responders and 70% in
non-responders (p=0.0002). Similarly, in a study by Pedersen
et al. 26 23% of infliximab dependent adult patients, 20% of
prolonged responders and 76% of non-responders had surgery
40 months after the start of therapy (pb0.001) (Fig. 2).
Thirty-nine per cent of infliximab treated children required
surgery in a study by de Ridder et al., 8 no specification
regarding treatment outcome has been described.
3.4. Are there any predictors of infliximab
dependency?
An association of dependent phenotype with perianal disease
and absence of intestinal surgery prior to infliximab therapy
has been found in one paediatric study.9 Contrary to this, the
paper from the Netherlands 8 reported that infliximabFootnote: ⁎corticosteroids, azathioprine or mercaptopurine or
, and colectomy) and/or perianal (fistulotomy, incision of abscess,






Wewer et al. 7 24 7 (29) 10 (42)
Duricova et al. 9 82 18 (22) 53 (66)
de Ridder et al. 8 66 15 (15) 37 (56)
Pedersen et al. *,26 245 114 (47) 71 (29)
n = number of patients treated with infliximab.
⁎study including adult patients.
85Drug dependency in inflammatory bowel diseasedependent response occurred significantly more in children
without fistulas than in those with fistulizing disease.
Two genetic variants (LTA c.207 ANG and CASP9 c.93 CNT)
have been suggested as conceivable predictors of long-term
and infliximab dependent outcome in a study of adult
patients,26 but needs to be confirmed.4. 5-ASA dependency
4.1. The development of the term 5-ASA
dependency
The most recently described dependent pattern has been in
therapy with 5-ASA preparations.17 Five hundred thirty-
seven CD patients treated at one centre in Denmark from
1953 to 2007 were retrospectively assessed for the use of 5-
ASA preparations. One hundred sixty-five (31%) of them had
monotherapy with 5-ASA and were evaluated according to
the phenotype model of 5-ASA dependency outlined in
Table 4.4.2. How many patients became 5-ASA dependent?
Out of 165 CD patients included, 36% obtained prolonged
response and 23% developed 5-ASA dependency.104.3. What does 5-ASA dependency imply in term of
surgery?
Patients responding to 5-ASA in a dependent way had a lower
cumulative probability of surgery during the disease course
compared with non-responders (32% vs. 61% at ten years
after diagnosis, p=0.02).104.4. Are there any predictors of 5-ASA dependency?
Female gender was identified as a predictor of prolonged
response and 5-ASA dependency. Sixty-eight percent of
women achieved prolonged response or developed 5-ASA
dependency compared to 51% of men (OR 2.89, 95%CI: 1.08–
7.75). Interestingly, patients with longer disease duration
(N3 years) were more likely to become 5-ASA dependent than
those with shorter disease course (38% and 18%; OR 4.06, 95%
CI: 1.09–15.1).10Fig. 3 summarizes the occurrence of drug dependencies
in therapy of corticosteroids, infliximab and 5-ASA
preparations.5. Discussion
Up to now, clinical, genetic and serological markers have been
of a little help when trying to predict patient's disease course
and deciding for long-term treatment management 27-29
and a good clinical predictor in daily clinical practice is still
lacking.
Drug dependency is dealing with a specific disease
phenotype, which to some extent determines patients'
prognosis. Hence it should not be understood as a simple
description of drug response only, but also as a clinical tool,
which can be used for identification of patients' phenotype
with a certain disease course and a need for maintenance
treatment.
To assess an impact of drug dependency on disease
prognosis, one has to consider the efficacy and safety profile
of the drug. Corticosteroids are highly efficacious anti-
inflammatory agents as the number needed to treat for the
induction of remission is three.30 Nevertheless, corticoste-
roid dependency is a condition connected with many side
effects, mainly growth retardation in children and further-
more associated with a high risk of surgery as obvious from
above mentioned studies.5,11 Therefore, early identification
of dependent patients, carrying a poor prognosis, is
important to introduce early immunomodulator therapy.
This has been suggested by results of a recent paediatric
population-based study from Denmark17. Despite the high
frequency of corticosteroid dependency in this cohort, the
cumulative probability of surgery was low for both CD and
UC. The frequent use of immunosuppressive preparations
among the children (68% of CD and 64% of UC children) could
probably explain this favourable outcome. Similar results
were found in two multicenter studies; only 8% of children
with CD and 5% with UC had a surgery one year after starting
steroids; nevertheless 81% and 61% of CD and UC patients
received immunomodulators and 28% and 12%, respectively,
infliximab within the observed year.20,21
Drug dependency, however, does not need to be only a
“negative” response phenotype as apparent from infliximab
dependency papers.9,26 The strong supportive evidence has
been provided mainly by the findings regarding surgical
intervention. One paediatric 9 and one adult 26 study have
shown a significantly lower cumulative probability of surgery
up to 50 months after treatment start in prolonged
responders as well as infliximab dependent patients com-
pared to non-responders. Of note is that infliximab depen-
dent children had a lower risk of undergoing surgery than
children with prolonged response. This suggests that in
patients responding in a dependent way the need for surgical
intervention could be at least postponed, if not avoided.
Thus, development of infliximab and corticosteroid depen-
dency might be considered as a useful prognostic marker,
which may indicate whether patient will benefit from
maintenance therapy (infliximab dependency) or should be
shifted to another immunosuppressive or biological treat-
ment (corticosteroid dependency).
Figure 2 The cumulative probability of intestinal surgery in Crohn's disease patients after the start of infliximab therapy (log-rank
test). Comparison with respect to long-term outcome: a) paediatric patients 9; and b) adult patients 26.
86 D. Duricova et al.So far, the safety profile of infliximab seems to be
favourable as outlined by national cohorts 31,32 and recently
also confirmed by meta-analysis 33. However, potentialadverse events can be very serious and life-threatening 34-37
and in recent period, there is an increasing evidence of
probably immunopathological adverse events induced by anti-
Table 4 Phenotype model of 5-Aminosalicylic acid (5-ASA) dependency.
Immediate outcome Long-term outcome
Complete response
Total regression of symptoms 30 days after 5-ASA initiation.
Prolonged response
Still in complete/partial response 1 year after induction
of response (maintained on 5-ASA
or after cessation of 5-ASA).
Partial response
Improvement of symptoms 30 days after 5-ASA initiation.
5-ASA dependency
Relapse ≤ 1 year after 5-ASA cessation regaining
complete/partial response after 5-ASA re-introduction
or
relapse on stable or reduced dose of 5-ASA requiring
dose escalation to regain response.
No response
No regression of symptoms ≤ 30 days with a need to shift
from 5-ASA to an immunomodulator or surgery.
No response
No regression of symptoms with a need to shift from
5-ASA to an immunomodulator or surgery.
87Drug dependency in inflammatory bowel diseaseTNF alpha therapy such as various skin eruptions and joint
problems.38,39 Therefore, the safety profile is always the
matter of concern. Identification of dependent and non-
dependent individuals might prevent “unnecessary” use of theFigure 3 Drug dependency in adults (a) and children (b) with inf
Aminosalicylic acid, ⁎ulcerative colitis.drug in non-dependent patients and so limit potential toxicity
in this group. Moreover, directing the therapy mainly to
dependent individuals could increase overall treatment
efficacy and lead to more effective allocation of resources.lammatory bowel disease — summary of the studies. 5-ASA = 5-
88 D. Duricova et al.This speculation might be supported by a recent prospective
withdrawal study with infliximab.40 Infliximab has been
discontinued in 115 patients with luminal CD who had been
treated with combined infliximab and immunosuppressive
therapy for at least one year and obtained a stable
corticosteroid-free remission. During the following 12 months
45 patients relapsed while more than half of the patients
maintained long-standing remission on immunosuppressors
without further need of infliximab treatment. Of note is that
re-introduction of infliximab in those relapsing induced a quick
remission in all but one patient and was well tolerated.40
Higher occurrence of infliximab dependency has been
observed in children compared to adults,7–9,26 whereas no
such difference has been seen in case of corticosteroids.
Based on previously published data, childhood-onset IBD
seems to be a different entity than adult-onset disease,
characterized by a more extensive disease and severe
phenotype.18,41,42 Moreover, higher remission rates have
been obtained in studies evaluating efficacy of infliximab in
children compared with adults.24,43 Biologicals are nowadays
considered the most potent therapy, reserved mainly for
patients refractory to conventional treatment including
corticosteroids.44 It can be only speculated whether the
observed differences between paediatrics and adults are a
consequence of the probably different natural courses of the
diseases in these two groups. New studies should confirm or
disprove these findings.
The most recent description of dependent response has
been in 5-ASA treatment of CD patients.10 Although the
efficacy of 5-ASA in CD is low as compared to above
mentioned drugs,30 the findings have demonstrated that
there is a certain, although small population of CD patients –
5-ASA dependent – which benefit from 5-ASA. Advantage of
5-ASA therapy is a high safety profile which is comparable to
placebo.45,46 Thus, in case the prescription of 5-ASA was
stopped in CD patients; this group would have to be exposed
to “stronger” but also more toxic preparations. Therefore,
the ongoing use of 5-ASA in CD would be of great benefit.
The future development of dependency definitions should
aim at more than 90% of patients would fit into the model,
thus leading to the coefficient of variations of b10%. In
practice, a pilot study including small group of patients
(about 20 individuals) is performed to evaluate if definitions
are generally applicable to patients' disease pattern. The
model is then adjusted until the desired goal is reached.
There are several factors having an impact on the rate of
drug dependencies, causing the difficulties when trying to
compare the outcomes of individual studies. Firstly, there is
heterogeneity of the definitions used. An attempt to
overcome this problem was made by implementing the
unified definition for corticosteroid dependency in the ECCO
guidelines. 22,23 Nevertheless, the use of the definitions in
daily clinical practice is still problematic. Secondly, the
recommended treatment policy has been changing over the
time. Immunosuppressives are nowadays introduced earlier,
mainly in paediatric population, to avoid corticosteroid
dependency.47,48 Infliximab is recommended as a long-term
maintenance treatment in all patients responding to
induction infusions;47,48 hence the frequency of infliximab
dependency may be biased. Further, the doctor preference
and economical possibilities have to be also considered.
Therefore, it is important that as the daily clinical practice isaltered over the time; the definitions are also adjusted
according to the actual requirements. This might be already
observed in the definition of corticosteroid dependency
proposed by Jakobsen et al.17 which has taken in account the
use of immunosuppressive or biological drugs in dependent
patients.
In the future, there is a need to assess the occurrence of
infliximab and 5-ASA dependency also in UC. Furthermore, in
addition to already described dependent phenotypes,
possible dependencies on other drugs used in IBD, like
azathioprine and adalimumab, should be studied and mainly
their prognostic value should be assessed.
6. Conclusion
Drug dependency is a specific disease phenotype which may
determine patients' disease course and therefore can be used
as a prognostic marker when deciding for treatment manage-
ment. Whereas corticosteroid dependency is considered to be
harmful condition, infliximab and 5-ASA dependency seem to
be beneficial. In daily clinic, early identification of dependent
patients might prevent serious consequences of corticosteroid
therapy aswell as probably improve patients' disease course by
maintaining infliximab treatment.
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